McClarren Financial Advisors Inc. Acquires Shares of 347 Stryker Co. (NYSE:SYK)

McClarren Financial Advisors Inc. bought a new position in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 347 shares of the medical technology company’s stock, valued at approximately $124,000.

A number of other large investors also recently modified their holdings of SYK. Dunhill Financial LLC lifted its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Stryker in the 3rd quarter worth about $36,000. Activest Wealth Management bought a new position in Stryker in the 4th quarter valued at about $36,000. Crews Bank & Trust acquired a new position in Stryker during the 4th quarter valued at about $39,000. Finally, Hara Capital LLC bought a new stake in Stryker during the 3rd quarter worth approximately $42,000. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by company insiders.

Stryker Trading Down 1.3 %

Shares of Stryker stock opened at $385.49 on Thursday. The stock has a market capitalization of $146.96 billion, a P/E ratio of 49.68, a P/E/G ratio of 2.98 and a beta of 0.96. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock’s 50-day simple moving average is $377.27 and its 200 day simple moving average is $366.01.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company earned $3.46 EPS. As a group, research analysts anticipate that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent research reports. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Stifel Nicolaus increased their target price on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, UBS Group increased their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $420.68.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.